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Abstract
Background: Bloodstream infection (BSI) due to Pseudomonas aeruginosa (Pa) has relevant clinical impact
especially in relation to drug resistance determinants. The PER-1 extended-spectrum beta-lactamase (ESBL) is a
common enzyme conferring high-level resistance to anti-pseudomonal cephalosporins. Risk factors and treatment
outcome of BSI episodes caused by PER-1-positive Pa (PER-1-Pa) strains were compared to those caused by ESBL-
negative Pa isolates (ESBL-N-Pa).
Methods: Twenty-six BSI cases due to ceftazidime-resistant Pa strains have been investigated. MIC values of anti-
pseudomonal drugs were determined by the Etest method (AB Biodisk, Solna, Sweden). The double-disk synergy
test was used to detect ESBL production. PCR amplification and DNA sequencing were used to characterize ESBL
types. Clinical records of BSI-patients were examined retrospectively. Demographic data, underlying diseases
(McCabe-Jackson classification and Charlson weighted index), risk factors, antimicrobial therapy, and treatment
outcome were evaluated in cases due to ESBL-positive and cases due to ESBL-N-Pa isolates. Unpaired Student's
t-test, Mann-Whitney U-test, Fisher's exact test and the χ2 test were used for statistical analysis.
Results: Nine Pa isolates expressed the PER-1 ESBL; the remaining 17 isolates did not produce ESBLs. Severe
sepsis (P = 0.03), bladder and intravascular catheters (both P = 0.01), immunosuppressive therapy (P = 0.04), and
mechanical ventilation (P = 0.03) were significantly associated with BSI due to PER-1-Pa. Empirical treatment (P =
0.02) and treatment after ID/AST (P < 0.01) were rarely adequate in PER-1-Pa cases. With regard to treatment
outcome, 77.8% BSI cases due to PER-1-Pa vs. 28.6% cases due to ESBL-N-Pa isolates failed to respond (P < 0.03).
All cases due to PER-1-Pa that were treated with carbapenems (alone or in combination with amikacin) failed to
respond. In contrast, 7/8 cases due to ESBL-N-Pa given carbapenems were responders.
Conclusion: Therapeutic failure and increased hospital costs are associated with BSI episodes caused by PER-1-
Pa strains. Thus, recognition and prompt reporting of ESBL-production appears a critical factor for the
management of patients with serious P. aeruginosa infections.
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Background
Pseudomonas aeruginosa (Pa) is commonly responsible for
nosocomial infections, including surgical site infection,
urinary tract infection, pneumonia, and bloodstream
infection (BSI) [1,2]. In particular, this organism is
responsible for 3–7% BSI cases [1,3-5]. Notably, high
morbidity and mortality rates (range 27% to 48%) have
been observed in critically ill patients [5,6].
Resistance to multiple drugs is a common feature of hos-
pital-acquired Pa strains [4,7,8]. Low permeability of the
outer membrane proteins (OMPs), production of the
inducible AmpC chromosomal β-lactamase, and multi-
drug efflux systems contribute to the intrinsic resistance of
this species [7]. Thus, drugs suitable against Pa infections
are limited to aminoglycosides (e.g., gentamicin, ami-
kacin), fluoroquinolones (ciprofloxacin remains the most
active), selected β-lactams (e.g., ceftazidime, carbapen-
ems), and one β-lactam/β-lactamase inhibitor combina-
tion (piperacillin/tazobactam) [4,5,7,8]. Unfortunately,
acquired resistance to different categories of the anti-pseu-
domonal agents is also possible and has been widely illus-
trated [7]. In particular, resistance to β-lactams is very
common and is due to mutations amplifying intrinsic
resistance mechanisms (i.e., AmpC), and/or acquisition
of additional β-lactamase genes by horizontal transfer
[7,8].
Acquired β-lactamases found in Pa isolates can be classi-
fied into three different groups: i) narrow-spectrum
enzymes (e.g., PSE-1/4) that efficiently degrade penicillins
and cefoperazone; ii) extended-spectrum β-lactamases
(ESBL) (e.g., PER-1, VEB-1, GES-1/2) that also degrade
cephems and monobactams; iii) metallo-β-lactamases
(MBL) (e.g., IMP-, VIM-type) that efficiently degrade all
anti-pseudomonal β-lactams with the exception of mono-
bactams [7,8].
The PER-1 ESBL is a class A enzyme conferring high-level
of resistance to anti-pseudomonal β-lactams and is one of
the most frequently ESBL detected in Pa [9-11]. PER-1 was
first detected in a urinary Pa isolate in a Turkish patient in
1991 [9,12]. Subsequently, it was frequently recognized
in Pa and Acinetobacter spp. isolates [13,14]. In 1997, our
group was the first to detect PER-1-positive Pa (PER-1-Pa)
isolates outside the geographical area of origin [15]. To
date, the PER-1 ESBL has been reported also from other
areas of Europe and Asia [16-19], and in different genera
and species (i.e., Alcaligenes faecalis, Salmonella tiphymu-
rium, P. mirabilis, Providencia spp.) [20-24].
Risk factors, empirical treatment and treatment outcome
of BSI due to Pa have been investigated by different
authors [25-28]. Particular emphasis has been posed on
clinical differences observed between multi-drug resistant
(MDR) and susceptible Pa isolates [6]. In contrast, the
clinical features of BSI caused by ESBL-positive Pa strains
have not been investigated.
We had the opportunity of studying 26 cases of BSI caused
by ceftazidime-resistant Pa (CAZ-R-Pa) of which 9 were
caused by PER-1-Pa strains. Microbiological and clinical
data have been compared to those of 17 BSI cases due to
ESBL-negative Pa isolates (ESBL-N-Pa). The impact of
PER-1 expression on risk factors and treatment outcome
was evaluated.
Methods
Sample collection and clinical data
Blood cultures were processed at the Microbiology Labo-
ratory of the Ospedale di Circolo e Fondazione Macchi
(Varese, Italy), an 800-bed university hospital that pro-
vides care in specialized areas such as heart surgery, neu-
rosurgery, hemato-oncology, kidney transplantation,
intensive care units (ICU). The study was performed in
conformity with the World Medical Association Declara-
tion of Helsinki and with the approval of the Hospital
Ethics Committee.
Clinical records of patients who developed BSI due to
CAZ-R-Pa strains in the period 1998–2004 were examined
retrospectively. The following data were studied: demo-
graphic data, primary source of infection leading to sec-
ondary BSI (when confirmed by culture), antimicrobial
agents administered during hospitalization, cause of
death. To categorize the severity of underlying diseases,
McCabe & Jackson classification scheme and Charlson
weighted index were used [29,30]. Severity of septicemia
was classified as described [31].
The following predisposing conditions (when present for
at least 72 hours before BSI onset) were also investigated:
mechanical ventilation, intravascular and bladder cathe-
ters, drainages (i.e., thoracic or abdominal), esophago-
gastroscopy, bronchoscopy, parenteral feeding, angiogra-
phy, renal dialysis, nephrostomy, and neutropenia. In
addition, previous surgery, previous use of antibiotics, use
of immunosuppressive drugs (e.g., corticosteroids, antin-
eoplastic agents) were taken into account when adminis-
tered for at least two weeks before BSI onset.
Definitions
Primary BSI refers to bacteremia for which no source of
infection was documented. BSI was defined as secondary
when laboratory evidence showed infection by the same
organism at a distant site. Antibiotic treatment was
defined as empirical when given before species identifica-
tion (ID) and antimicrobial susceptibility tests (AST).
Treatment was considered adequate when the responsibleBMC Infectious Diseases 2006, 6:52 http://www.biomedcentral.com/1471-2334/6/52
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Pa strain was subsequently found susceptible to the
administered drug(s).
Treatment outcome of patients was classified as follows:
(i) "complete response", resolution of fever, leukocytosis,
and local signs and symptoms of infection; (ii) "partial
response", improvement of fever, leukocytosis, and local
signs and symptoms of infection without complete reso-
lution; (iii) "relapse", recurrence of infection with the
same organism at any body site within 1 month after dis-
continuation of therapy; (iv) "treatment failure", absence
of resolution or worsening of signs and symptoms of
infection; (v) "not assessable", incomplete records or
death of the patient within 72 hours of BSI onset. BSI-
patients who had complete or partial response to treat-
ment were considered as "responders", whereas those
who had relapse or treatment failure were considered as
"nonresponders". Treatment outcome was attributed to
the drug(s) that were administered after receiving the
microbiological report containing ID and AST results.
Death was considered as attributable to BSI when
occurred within 7 days of BSI diagnosis or when the
patient was still under treatment. The 28-day mortality
rate was also reported. Follow-up of patients that were dis-
charged or transferred to a different hospital within 1
month of BSI onset was performed in collaboration with
the caring physicians.
Microbiological methods
Blood cultures were incubated for at least 5 days using the
BACTEC 9240 instrument (Becton Dickinson Diagnostic
Systems, Sparks, MD). Results were interpreted according
to guidelines of the Centers for Diseases Control and Pre-
vention [32]. Isolates obtained from blood cultures of the
same patient after at least 7 days of a previous BSI episode
were considered as causing a new BSI episode [32].
Table 1: Antimicrobial susceptibility test and molecular results for all ceftazidime-resistant P. aeruginosa isolates (n = 26) responsible of 
bloodstream infections (BSI)
Isolates MIC of agents (µg/ml) a Type of enzymes 
produced
PIP TZP CAZ FEP ATM IMP MEM CIP AMK GEN
338/98 > 256 > 256 > 256 128 > 256 8 32 > 32 64 > 256 AmpC, PER-1
LS034/99 > 256 > 256 > 256 > 256 > 256 > 32 > 32 > 32 64 > 256 AmpC, PER-1
140/99 > 256 > 256 > 256 64 > 256 16 32 > 32 64 > 256 AmpC, PER-1
47/00 > 256 > 256 > 256 128 > 256 16 8 > 32 16 > 256 AmpC, PER-1
324/00 > 256 > 256 > 256 > 256 > 256 > 32 16 > 32 16 > 256 AmpC, PER-1
A360/00 > 256 > 256 > 256 > 256 > 256 > 32 16 > 32 16 > 256 AmpC, PER-1
527/00 > 256 > 256 > 256 > 256 > 256 > 32 32 > 32 16 > 256 AmpC, PER-1
2126/01 > 256 > 256 > 256 64 > 256 16 8 > 32 32 > 256 AmpC, PER-1
A150/02 > 256 > 256 > 256 48 > 256 > 32 32 > 32 > 256 > 256 AmpC, PER-1
299/98 > 256 128 32 64 32 2 2 0.094 4 8 AmpC
77/99 > 256 64 64 16 64 4 2 0.5 8 8 AmpC
251/00 > 256 128 16 32 16 2 4 > 32 128 > 256 AmpC
746/00 > 256 64 16 64 16 8 8 > 32 96 > 256 AmpC
2497/01 > 256 128 16 128 16 2 1 0.125 8 > 256 AmpC
2544/01 256 64 32 128 64 16 2 0.5 16 > 256 AmpC
A372/02 64 32 16 32 32 0.5 0.5 > 32 32 > 256 AmpC
A480/02 > 256 64 64 16 8 > 32 16 0.094 1 4 AmpC
659/02 96 32 32 16 16 1 0.5 > 32 8 > 256 AmpC
694/02 128 64 16 8 16 4 8 > 32 16 > 256 AmpC
A276/03b 64 32 32 16 16 1 0.5 > 32 16 > 256 AmpC
A562/03b 64 16 32 16 16 1 0.5 > 32 16 > 256 AmpC
A173/03b 3 2 4 3 21 61 61 0 . 5 >  3 2 4 8 A m p C
A189/03 c 32 16 32 16 8 1 0.5 > 32 8 > 256 AmpC
A590/03 > 256 128 64 8 64 32 8 0.125 0.5 2 AmpC
A424/04 > 256 64 64 4 32 4 2 0.094 1 4 AmpC
A567/04 c 1 2 8 6 46 41 61 61 0 . 5 0 . 1 2 5 0 . 52 A m p C
a MIC values were obtained using the Etest method (AB Biodisk). Abbreviations of antimicrobial agents and breakpoints for susceptibility (S) and 
resistance (R) are given: PIP, piperacillin (S ≤ 64, R ≥ 128); TZP, piperacillin plus tazobactam (S ≤ 64, R ≥ 128); CAZ, ceftazidime (S ≤ 8, R ≥ 32); FEP, 
cefepime (S ≤ 8, R ≥ 32); ATM, aztreonam (S ≤ 8, R ≥ 32); IPM, imipenem (S ≤ 4, R ≥ 16); MEM, meropenem (S ≤ 4, R ≥ 16); CIP, ciprofloxacin (S ≤ 
1, R ≥ 4); AMK, amikacin (S ≤ 16, R ≥ 64); GEN, gentamicin (S ≤ 4, R ≥ 16).
b These strains caused three different BSI in the same patient.
c Only microbiological data were available. Therefore, these 2 cases were excluded from statistical analysis of demographic data, risk factors and 
treatment outcome.BMC Infectious Diseases 2006, 6:52 http://www.biomedcentral.com/1471-2334/6/52
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ID and AST were routinely achieved by the Sceptor System
(Becton Dickinson) during 1998–2002 or the Phoenix
System (Becton Dickinson) since 2003. ID results were
confirmed using the ID32GN strips (Bio-Mérieux, Marcy
L'Étoile, France). Pa isolates causing BSI were stored at -
80°C in Todd-Hewitt broth supplemented with 20% glyc-
erol for further investigations.
Minimum inhibitory concentration (MIC) values were
determined by the Etest method (AB Biodisk, Solna, Swe-
den). Susceptibility categories were determined according
to current criteria of the Clinical Laboratory Standards
Institute, CLSI [33]. The reference P. aeruginosa strain
ATCC 27853 was used as control.
Screening of ESBL-producing isolates
To screen for ESBL producing strains, CAZ-R-Pa isolates
(MIC > 8 µg/ml) were tested using the double-disk syn-
ergy test on Mueller-Hinton agar plates with disks con-
taining 30 µg of aztreonam, ceftazidime, and cefepime
placed 20 mm apart (center to center) around a disk con-
taining amoxicillin (20 µg) plus clavulanic acid (10 µg).
Enhancement of the inhibition zone – indicating synergy
between clavulanic acid and any test drugs – was taken as
presumptive evidence of ESBL production. To detect pos-
sible MBL producers, CAZ-R-Pa were also screened with
Etest strip containing imipenem and imipenem plus
EDTA (AB Biodisk).
β-lactamase characterization by isoelectric focusing (IEF)
Supernatants of crude bacterial lysates obtained by soni-
cation were studied with IEF using a polyacrylamide gel
containing Pharmalyte anpholines (pH range, 3.5 to
10.0) (Pharmacia, Milan, Italy). Gels were run for 3 hours
at 10 W and 4°C using a Multiphor II system (Pharmacia).
β-lactamase bands were evidenced with 1 mM nitrocefin
as chromogenic substrate (Oxoid, Milan, Italy) in 0,1 M
phosphate buffer (pH 7.0) [15]. Estimations of pI values
were made by comparison with extracts of reference bac-
terial strains producing the PER-1 (5.3), TEM-1 (5.4),
TEM-2 (5.6), TEM-3 (6.3), and SHV-1 (7.6) enzymes.
Molecular studies for confirming the PER-1 determinant
Colony blot hybridization and Southern blot hybridiza-
tion were carried out as described [15]. The probe used in
filter hybridization experiments was a PCR-generated
amplicon comprising the entire blaPER-1  open reading
frame labeled with 32P by the random priming technique
[12,20].
PCR amplification of blaPER  alleles was performed as
described on crude DNA extracts [20]. The blaPER-1 and bla-
PER-2 genes were distinguished by digestion with PvuII and
StuI; the amplicon sequence was determined on crude
amplification products as described [20].
Statistical analysis
Statistical analysis was performed using the Statistica PC
software (StatSoft, Tulsa, OK). Variance by logistic regres-
Table 2: Demographic data and severity of the underlying disease of analyzed patients (n = 22) with BSI due to ceftazidime-resistant P. 
aeruginosa strains: difference between PER-1-positive (PER-1-P-Pa) and ESBL-negative Pa (ESBL-N-Pa) isolates.a
Demographic and clinical parameters PER-1-Pa ESBL-N-Pa P value b
No. BSI-patients 9 13 -
Male/Female 7/2 11/2 -
Age, mean year ± SD 58.0 ± 22.1 63.4 ± 17.7 NS
Patient location
- Medical 3 (33.3) 7 (53.8) NS
- Surgical 0 (0.0) 2 (15.4) NS
- ICU 6 (66.7) 4 (30.8) 0.10
McCabe & Jackson groups
- Nonfatal 6 (66.7) 5 (38.5) NS
- Ultimately fatal 1 (11.1) 5 (38.5) NS
- Rapidly fatal 2 (22.2) 3 (23.1) NS
Charlson weighted index, mean ± SD 2.9 ± 2.57 3.5 ± 2.6 NS
Previous hospitalizations (during the last 12 months) 5 (55.6) 9 (69.2) NS
Previous use of antibiotics (during the last 12 months) 5 (55.6) 7 (53.8) NS
Hospital-acquired BSI 9 (100) 9 (69.2) 0.07
Mean length of hospital stay (MLHS), mean ± SD (days) 69.3 ± 58.0 41.6 ± 35.3 0.09
- MLHS before BSI diagnosis, mean ± SD (days) 22.9 ± 8.0 17.1 ± 24.0 NS
- MLHS after the BSI, mean ± SD (days) 46.4 ± 57.5 24.4 ± 20.6 0.11
28-day mortality 2 (22.2) 1 (7.7) NS
Mortality attributable to BSI (within 7 days of onset) 1 (11.1) 0 (0.0) NS
a Data are expressed as no. (%) of patients, unless otherwise indicated.
b -, not calculated; NS, not significant.BMC Infectious Diseases 2006, 6:52 http://www.biomedcentral.com/1471-2334/6/52
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sion was calculated in order to compare patient groups
infected by PER-1-Pa or ESBL-N-Pa isolates. The Student's
unpaired t-test was used to compare continuous variables,
and the Mann-Whitney U-test to compare not normally
distributed continuous variables. Fisher's exact test and
the  χ2 test were used to compare treatment outcome
between patient groups. Differences were considered sta-
tistically significant when 2-tailed P value was ≤ 0.05.
Results
Microbiological data of isolates causing BSI
During the study period (January 1998 to September
2004), 122 strains of Pa causing BSI in adult patients were
stored at -80°C. On the basis of Etest method, CAZ-R-Pa
isolates were 26/122 (21.3%). Suspect MBL-producing
strains were not detected. The double-disk synergy test
showed that 9/26 isolates (34.6%) were ESBL-positive.
IEF analysis showed that supernatants of the 26 CAZ-R-Pa
isolates exhibited a band at pI 8.0–8.4 associated to the
expression of the chromosomal AmpC enzyme. All dou-
ble-disk positive strains (9/26) showed an additional
band at pI 5.3 compatible with the expression of the PER-
1 enzyme. Molecular analysis confirmed that all isolates
showing nitrocephin hydrolysis at pI 5.3 produced the
PER-1 ESBL (data not shown).
As shown in Table 1, PER-1-Pa isolates were consistently
resistant to anti-pseudomonal drugs: ceftazidime (MIC
>256 µg/mL), cefepime (MIC >48 µg/mL), carbapenems
(MIC >8 µg/mL), piperacillin/tazobactam (MIC >256 µg/
mL), ciprofloxacin (MIC >32 µg/mL), and gentamicin
(MIC >256 µg/mL). Only 4 isolates had amikacin MIC
values into the susceptibility range (MIC, 16 µg/mL).
ESBL-N-Pa strains showed reduced susceptibility to all
extended-spectrum cephalosporins; carbapenems were
the most active β-lactams (70.6% susceptible isolates).
Concerning other drugs, resistance to ciprofloxacin and
gentamicin was common (52.9 and 76.5%, respectively).
Amikacin-resistant strains were only 3/17 (17.6%).
Risk factors for BSI caused by PER-1-Pa isolates
Twenty-six cases of BSI due to CAZ-R-Pa isolates were
observed in 24 patients (one patient was affected by 3 dif-
ferent episodes of bacteremia). Since clinical data of 2
patients affected by one BSI episode were not available
Table 3: Clinical parameters of investigated BSI cases (n = 24) due to ceftazidime-resistant P. aeruginosa strains: difference between 
PER-1-positive (PER-1-Pa) and ESBL-negative (ESBL-N-Pa) isolates.a
Clinical parameters PER-1-Pa ESBL-N-Pa P value b
No. BSI episodes 9 15c -
Severity of septicemia
- Sepsis 5 (55.6) 12 (80.0) NS
- Severe sepsis 4 (44.4) 1 (6.7) 0.03
- Septic shock 0 (0.0) 2 (13.3) NS
Empirical treatment provided 8 (88.9) 14 (93.3) NS
- Adequate 1 (11.1) 9 (60.0) 0.02
Adequate treatment after ID / AST d results 1 (11.1) 12 (80.0) < 0.01
Predisposing factors for BSI infection
- Bladder catheter 9 (100) 7 (46.7) 0.01
- Previous use of antibiotics 8 (88.9) 9 (60.0) NS
- Intravascular catheter 9 (100) 7 (46.7) 0.01
- Immunosuppressive therapy 5 (55.6) 5 (33.3) 0.04
- Previous surgery 7 (77.8) 5 (33.3) NS
- Drainages 2 (22.2) 5 (33.3) NS
- Mechanical ventilation 6 (66.7) 3 (20.0) 0.03
- Esophagogastroscopy 1 (11.1) 2 (13.3) NS
- Other 4 (44.4) e 4 (26.6) f -
Overall secondary BSI 5 (55.6) 10 (66.7) NS
- Urinary tract 2 (22.2) 3 (20.0) NS
- Respiratory tract 3 (33.3) 4 (26.7) NS
- IV catheter 1 (11.1) 1 (6.7) NS
- Wounds 0 (0.0) 4 (26.7) NS
a Data are expressed as no. (%) of patients.
b -, not calculated; NS, not significant.
c One patient was affected by three different BSI episodes.
d ID, identification; AST, antimicrobial susceptibility tests.
e Bronchoscopy (n = 1), dialysis (n = 1), parenteral feeding (n = 1), angiografhy (n = 1), and neutropenia (n = 1).
f Bronchoscopy (n = 1), dialysis (n = 1), parenteral feeding (n = 1), nephrostomy (n = 1), and neutropenia (n = 1).BMC Infectious Diseases 2006, 6:52 http://www.biomedcentral.com/1471-2334/6/52
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(cases A189/03 and A567/03), statistical analysis was per-
formed considering only 22 patients affected by 24 BSI
cases.
Demographic data and severity of underlying diseases of
BSI-patients infected by PER-1-Pa and ESBL-N-Pa isolates
are shown in Table 2. Chance of developing hospital-
acquired BSI and greater mean length of hospital stay
(MLHS) might be related to infection by PER-1-positive
strains, though differences were not statistically signifi-
cant (P = 0.07 and P = 0.09, respectively). Clinical param-
eters of BSI cases due to PER-1-Pa and ESBL-N-Pa isolates
are shown in Table 3. Severe sepsis (P = 0.03), bladder and
intravascular catheters (both, P = 0.01), immunosuppres-
sive therapy (P = 0.04), and mechanical ventilation (P =
0.03) were significantly associated with BSI due to PER-1-
Pa isolates. Empirical treatment and treatment after ID/
AST were significantly less adequate in the PER-1-Pa than
in the ESBL-N-Pa group (P = 0.02 and P <0.01, respec-
tively).
Treatment outcome of BSI caused by PER-1-Pa isolates
Clinical parameters, antimicrobial regimens and treat-
ment outcome for each BSI episode due to PER-1-Pa and
ESBL-N-Pa isolates are summarized in Table 4 and Table
5, respectively.
Patients infected by PER-1-Pa strains were treated as fol-
lows: carbapenems (n = 4), carbapenems plus amikacin
(n = 3), cefepime plus amikacin (n = 1), and ciprofloxacin
(n = 1). Those infected by ESBL-N-Pa strains were treated
with: carbapenems (n = 9), ciprofloxacin (n = 2), pipera-
cillin/tazobactam (n = 2), piperacillin/tazobactam plus
amikacin (n = 1), and amikacin (n = 1). One patient given
imipenem was excluded from statistical analysis since he
was transferred to a different hospital just one day after
BSI onset (case #251/00).
Overall, 7/9 (77.8%) cases due to PER-1-Pa vs. 4/14
(28.6%) cases due to ESBL-N-Pa isolates failed to respond
(P < 0.03). In particular, 5/7 BSI cases due to PER-1-Pa
strains failed to respond to carbapenems (alone or in
combination with other drugs), while 7/8 cases due to
ESBL-N-Pa isolates responded satisfactorily to carbapen-
ems. With regard to amikacin, 4/4 BSI cases due to PER-1-
Pa vs. 1/2 cases due to ESBL-N-Pa strains failed to
respond. Notably, 3/3 cases due to PER-1-Pa that were
treated with carbapenems plus amikacin failed to
respond.
Discussion
The clinical impact of ESBL-production in P. aeruginosa
isolates causing BSI received little attention since Pa pro-
duces a small percentage of BSI cases and this species
rarely harbors ESBLs [1,3-5]. The increasing circulation of
Table 4: Clinical parameters, antimicrobial regimens and treatment outcome of patients with bloodstream infection (BSI) due to PER-
1-positive P. aeruginosa (PER-1-Pa) isolates
Isolate Age 
(yr)
Sex a McCabe 
& 
Jackson b
Charlson 
weighted 
index
Primary 
source(s)
of infection c
Severity of 
septicemia
Empirical treatment Treatment administered after ID
and AST d results
Treatment 
outcome e
Agent
(daily dose)
Adequate Agent
(daily dose)
Timing 
from 
BSI onset
Duration
(days)
338/98 58 M NF 1 Unknown Severe 
sepsis
SXT (10 ml × 3) No AMK (0.5 g × 2)
FEP (2 g × 3)
Day 4
Day 7
10
11
FA
LS034/99 60 M NF 0 LRTI Severe 
sepsis
IPM (1.5 g × 3) No IPM (1.5 g × 3)
AMK (0.5 g × 2)
Day -21
Day -2
53
8
RE
140/99 69 M NF 1 Unknown Severe 
sepsis
CTX (2 g × 3)
IPM (0.5 g × 3)
No Not changed Day -15
Day 0
20
5
FA
47/00 19 F NF 6 LRTI, IVC Sepsis MEM (1 g × 2)
AMK (1 g)
Yes MEM (1 g × 3)
AMK (1 g)
Day 1 6
18
FA
324/00 27 M NF 0 Unknown Sepsis CIP (0.4 g × 2) No Not changed Day 0 13 RE
A360/00 72 M RF 6 LRTI Sepsis None No MEM (0.5 g × 4)
AMK (0.75 g)
Day 3
Day 3
13 18 RE
527/00 60 M NF 3 Unknown Sepsis IPM (0.5 g × 4) No Not changed Day -9 13 CR
2126/01 67 F RF 6 UTI Sepsis CRO (2 g) No IPM (1 g × 3) Day 3 8 PR
A150/02 90 M UF 3 UTI Severe 
sepsis
CIP (0.2 g × 2)
TZP (2 g × 2)
No IPM (0.5 g × 2) Day 1 11 RE
Abbreviations for antimicrobial agents: SXT, trimethoprim-sulfametoxazole; PIP, piperacillin; TZP, piperacillin plus tazobactam; CRO, ceftriaxone; 
FEP, cefepime; IPM, imipenem; MEM, meropenem; CIP, ciprofloxacin; AMK, amikacin; GEN, gentamicin.
a Sex: F, female; M, male.
b McCabe & Jackson classification: NF, nonfatal; UF, ultimately-fatal; RF, rapidly-fatal.
c Primary source(s) of infection: LRTI, lower respiratory tract infection; IVC, intravascular catheter colonization; UTI, urinary tract infection.
d ID, identification; AST, antimicrobial susceptibility test.
e Treatment outcome: CR, complete response; PR, partial response; FA, failure; RE, relapse.BMC Infectious Diseases 2006, 6:52 http://www.biomedcentral.com/1471-2334/6/52
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ESBL determinants in this species underlines the need of
studying this issue [19,14,24]. In some geographic areas
such as Northern Italy, high incidence of PER-1-positive P.
aeruginosa has been recently reported [19]. This retrospec-
tive analysis was undertaken to evaluate the clinical fea-
tures of BSI episodes due to PER-1-Pa isolates. Twenty-six
BSI episodes due to CAZ-R-Pa isolates (nine of which pro-
duced the PER-1 enzyme) that occurred over a 7-year
period have been studied. Five out of 9 PER-1-Pa strains
were clonally related and were collected during an out-
break that occurred at our hospital [15].
As reported in the case of ESBL-producing enterobacteria
[24], risk factors such as bladder and intravascular cathe-
ters, immunosuppressive therapy, mechanical ventilation
were significantly associated with BSI episodes caused by
PER-1-Pa isolates. This result may be explained by the fact
that cases due to PER-1-Pa were most prevalent among
ICU patients. The overall MLHS and MLHS after BSI onset
were greater in cases due to PER-1-Pa than in cases due to
ESBL-N-Pa isolates (in both cases the MLHS was increased
by approximately 20 days). This finding highlights the
impact of ESBL-positive Pa strains on hospital costs [34].
In Italy, the average hospital day cost is approximately
500 Euro (Agenzia per i Servizi Sanitari Regionali, http://
www.assr.it). Thus, the hospital cost of each patient with
PER-1-Pa-induced BSI is approximately 10,000 Euro
higher than that of patients with BSI due to ESBL-negative
Pa.
The PER-1-Pa isolates collected at our institution were
resistant to virtually all anti-pseudomonal drugs. This
finding justifies the observed high rates of inadequate
empirical and rational treatments. Inadequate treatment
was, in fact, significantly higher in cases due to PER-1-Pa
as compared to cases due to ESBL-N-Pa. It should be
emphasized that inappropriate initial therapy in Pa BSI
has been associated with worse outcome [27,28]. Our
data, however, do not confirm the above findings. In fact,
despite that only 10/24 (41.7%) cases infected by CAZ-R-
Pa isolates received adequate empirical treatment, the
overall mortality rate was 13.6% (cases #140/99, #2126/
01, and #A372/02). In particular, 8/9 patients infected
with PER-1-Pa isolates received inadequate empirical
Table 5: Clinical parameters, antimicrobial regimens and treatment outcome of patients with bloodstream infection (BSI) due to 
ESBL-negative P. aeruginosa (ESBL-N-Pa) isolates
Isolate Age (yr) Sex a McCabe 
& 
Jackson b
Charlson 
weighted
index
Primary 
source(s)
of 
infection c
Severity of
septicemia
Empirical
treatment
Treatment administered after
ID and AST d results
Treatment
outcome e
Agent
(daily dose)
Adequate Agent
(daily dose)
Timing 
from
BSI onset
Duration
(days)
299/98 40 M NF 0 LRTI, WI Septic 
shock
IPM (1 g × 3) Yes Not changed Day 1 12 FA
77/99 76 M UF 4 LRTI, UTI Sepsis IPM (0.5 × 3) Yes Not changed Day 0 14 CR
251/00 55 M UF 6 Unknown Sepsis IPM (0.5 g × 2) Yes Not changed Day -1 1 NA
746/00 64 M NF 2 UTI Sepsis PIP (2 g × 2)
CIP (0.5 g)
No IPM (0.5 g × 2) Day 5 7 CR
2497/01 34 M NF 1 Unknown Sepsis PIP (2 g × 2) No CIP (0.5 g × 2) Day 5 3 CR
2544/01 79 F UF 3 Unknown Sepsis NET (0.15 g × 2) No IPM (0.5 g × 3) Day 1 13 CR
A372/02 67 M RF 7 WI Severe 
sepsis
CIP (0.5 g × 2)
AMK (0.5 g × 2)
No IPM (0.5 × 2) Day 4 9 CR
A480/02 69 F NF 0 LRTI, WI Sepsis CIP (0.4 g × 2) Yes Not changed Day 1 10 FA
659/02 71 M RF 8 UTI Sepsis IPM (0.5 g × 2) Yes Not changed Day 0 8 CR
694/02 93 M UF 3 IVC Sepsis PTZ (2.25 g × 3) Yes PTZ (2.25 g × 3)
AMK (0.5 g × 2)
Day 0
Day 6
7 2 CR
A276/03f 76 M NF 3 Unknown Sepsis None No IPM (1 g × 3) Day 3 10 PR
A562/03f 76 M NF 3 Unknown Sepsis PTZ (2.25 g × 3) Yes Not changed Day 0 15 CR
A173/03f 76 M NF 3 Unknown Sepsis PTZ (2.25 g × 3) Yes Not changed Day -1 29 CR
A590/03 64 M RF 6 LRTI, WI Sepsis IPM (1 g × 3) 
AMK (0.75 g)
Yes AMK (1 g) Day 2 8 RE
A424/04 36 M UF 3 Unknown Septic 
shock
IPM (0.5 g × 4) No MEM (1 g × 2) Day 4 19 FA
Abbreviations for antimicrobial agents: NET, netilmicin; PIP, piperacillin; TZP, piperacillin plus tazobactam; CRO, ceftriaxone; FEP, cefepime; IPM, 
imipenem; MEM, meropenem; CIP, ciprofloxacin; AMK, amikacin; GEN, gentamicin.
a Sex: F, female; M, male.
b McCabe & Jackson classification: NF, nonfatal; UF, ultimately-fatal; RF, rapidly-fatal.
c Primary source(s) of infection: LRTI, lower respiratory tract infection; WI, wound infection; UTI, urinary tract infection; IVC, intravascular catheter 
colonization.
d ID, identification; AST, antimicrobial susceptibility test.
e Treatment outcome: CR, complete response; PR, partial response; FA, failure; RE, relapse; NA, not assessable.
f These strains caused three different BSI in the same patient.BMC Infectious Diseases 2006, 6:52 http://www.biomedcentral.com/1471-2334/6/52
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treatment, but only 1 (case #140/99) died for causes
attributable to BSI. In this group, however, most patients
who survived were young and had non-fatal underlying
diseases [27].
With regard to PER-1 expression, significant responsibility
of this determinant on mortality has been reported from
Turkey [35]. The present results fail to confirm this con-
clusion. Not significantly different death rates were in fact
observed between patients infected with PER-1-Pa and
ESBL-N-Pa isolates. Though this may be related to the low
number of BSI cases investigated by us, the Turkish study
investigated infections of different body sites comparing
those caused by PER-1-positive isolates with those pro-
duced by Pa strains with variable resistance profiles [35].
Our study was instead focused only on BSI cases due to
CAZ-R-Pa isolates harboring or not the PER-1 determi-
nant.
The overall treatment outcome of BSI-patients infected by
ESBL-negative strains was significantly better than that of
patients infected by PER-1-Pa (P < 0.03). In particular,
monotherapy with carbapenems was adequate only in BSI
cases due to ESBL-N-Pa isolates. Concerning amikacin,
only 4/9 isolates of PER-1-Pa were in the susceptibility
range, but the two BSI-patients receiving adequate treat-
ment with this drug (cases A360/00 and 47/00) were clas-
sified as nonresponders. In the latter two cases, amikacin
MIC (16 µg/mL) was close to the susceptibility breakpoint
(≤ 16 µg/mL) [33]. Treatment failure could be ascribed to
the inability of the drug to reach adequate tissue concen-
trations, especially at sites where high numbers of bacteria
were present.
Though combination therapy is usually recommended for
severe Pa infections [2,7,27], three patients affected by BSI
due to PER-1-Pa isolates failed to respond to carbapenems
plus amikacin. Treatment outcome results appear to indi-
cate that combinations of carbapenems plus aminoglyco-
sides are not reliable options for severe infections caused
by PER-1-Pa isolates. Mimoz and colleagues studying
experimental pneumonia in rats showed that imipenem
plus amikacin produced optimal results against a PER-1-
Pa isolate [36]. The observed inability of imipenem plus
amikacin to resolve BSI cases might reflect the expression
of additional resistance mechanisms. It is hardly believa-
ble that the association of AmpC and PER-1 enzymes is
responsible for carbapenem resistance in P. aeruginosa.
Additional mechanisms (OMPs alterations, efflux pumps)
might thus be operative in carbapenem-resistant strains. A
role of OMPs modifications appear likely, since 6/9 PER-
1-Pa isolates showed imipenem MIC values higher than
those of meropenem. This may indicate that mutations
leading to decreased expression of the OprD porin could
be responsible for differences in susceptibility to imi-
penem and meropenem [7].
Conclusion
Our study shows that therapeutic failure and increased
hospital costs are associated with BSI episodes due to PER-
1-Pa strains. The existing therapeutic options for Pa iso-
lates carrying ESBL determinants are still inadequate.
Thus, recognition and prompt reporting of ESBL-produc-
tion appears a critical factor for the management of
patients with serious P. aeruginosa infections. The possible
role of old antimicrobials such as colistin should be re-
evaluated [37].
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